Ras pathway activation in gliomas: A strategic target for intranasal administration of perillyl alcohol

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 4, 2008, Pages 267-276

  Fonseca, Clovis Orlando Da ^a   Linden, Rafael ^b   Futuro, Débora ^c   Gattass, Cerli Rocha ^b   Quirico Santos, Thereza ^b,c  

^a HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Gliomas; Intranasal administration; Perillyl alcohol; Ras

Indexed keywords

ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CORTICOSTEROID DERIVATIVE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOPROTEIN; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PERILLYL ALCOHOL; PHENOBARBITAL; PHENYTOIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE B; RAS PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN ABSCESS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRANIOTOMY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MOUSE; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MONOTERPENES; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 50649118313     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0027-0     Document Type: Article

References (31)

1. Bahl J. J., De Armond R. L. and Bressler R. (2004): Multisite inhibition by phenylacetate of PC-3 cell growth. Anticancer Drugs, 15, 513-523.
2. Bailey H. H., Attia S., Love R. R., Fass T., Chappell R., Tutsch K., Harris L., Jumonville A., Hansen R., Shapiro G. R. and Stewart J. A. (2008): Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother. Pharmacol., 62, 149-157.
3. Bailey H. H., Wilding G., Tutsch K. D., Arzzomanian R. Z., Albert D., Feierabend C., Simon K., Marnocha R., Holstein S. A., Stewart J., Lewis K. and Hohl R. J. (2004): A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother. Pharmacol., 54, 368-376.
4. Brat D. J., Scheithauer B. W., Fuller G. N. and Tihan T. (2007): Newly Codified Glial Neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: Angiocentric Glioma, Pilomyxoid strocytoma and Pituicytoma. Symposium: The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: Newly Codified Entities.
5. Buechler R. D. and Peffley D. M. (2004): Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis. Mol. Carcinog., 41, 39-53.
6. Campbell P. M., Groehler A. L., Lee K. M., Ouellette M. M., Khazak V. and Der C. J. (2007): K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res., 67, 2098-2106.
7. Da Fonseca C. O. (2004): Effects of in vivo and in vitro treatment of monoterpene perillyl alcohol on proliferation and gene expression control of high grade gliomas. Arq. Neuro-Psiquiatr., 62, 1117-1118.
8. Da Fonseca C. O., Landeiro J. A., Clark S. S., Quirico-Santos T., Da Costa Carvalho M. G. and Gattass C. R. (2006): Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg. Neurol., 65 (suppl. 1), S2-8.
9. Da Fonseca C. O., Masini M., Futuro D., Caetano R., Gattass R. C. and Quirico-Santos T. (2006): Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review. Surg. Neurol., 66: 611-615.
10. Duncan R. E., Lau D., El-Sohemy A. and Archer M. C. (2004): Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem. Pharmacol., 68, 1739-1747.
11. Feldkamp M. M., Lau N., Roncari L. and Guha A. (2001): Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res., 61, 4425-4431.
12. Fernandes J., Fonseca C.O., Teixeira A. and Gatass C. R. (2005): Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells. Oncol. Rep., 13, 943-947.
13. Franco-Hernández C., Martínez-Glez V. and Rey J. A. (2007): Biology molecular of glioblastomas. Neurocirugia, 18, 373-382.
14. Guha A., Feldkamp M. M., Lau N., Boss G. and Pawson A. (1997): Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene, 15, 2755-2765.
15. Hofer S. and Herrmann R. (2001): Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J. Cancer Res. Clin. Oncol., 127, 91-95.
16. Holstein S. A. and Hohl R. J. (2003): Monoterpene regulation of Ras and Ras-related protein expression. J. Lipid Res., 44, 1209-1215.
17. Huanbiao M. O. and Elson C. E. (2004): Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med., 229, 567-585.
18. Inda M. M., Fan X., Muñoz J., Perot C., Fauvet D., Danglot G., Palacio A., Madero P., Zazpe I., Portillo E., Tuńón T., Martínez-Peńuela J.M., Alfaro J., Eiras J., Bernheim A. and Castresana J. S. (2003): Chromosomal abnormalities in human glioblastomas: gain in chromosome 7p correlating with loss in chromosome 10q. Mol. Carcinog., 36, 6-14.
19. Jeuken J. W., Sprenger S. H., Vermeer H., Kappelle A. C., Boerman R. H. and Wesseling P. (2002): Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J. Neurosurg., 96, 559-564.
20. Jeuken J., van den Broecke C., Gijsen S., Boots-Sprenger S. and Wesseling P. (2007): RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol., 114, 121-133.
21. Karp J. E. and Lancet J. E. (2007): Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest., 25:484-494.
22. Konstantinopoulos P. A., Karamouzis M. V. and Papavassiliou A. G. (2007): Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov., 6, 541-555.
23. Mischel P. S. and Cloughesy T. F. (2003): Targeted molecular therapy of GBM. Brain Pathol., 13, 52-61.
24. Neyns B., Chaskis C., Joosens E., Menten J., D'Hondt L., Branle F., Sadones J., Michotte A. (2208): A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest., 26, 269-277.
25. Nigro J. M., Misra A., Zhang L., Smirnov I., Colman H., Griffin C., Ozburn N., Chen M., Pan E., Koul D., Yung W. K., Feuerstein B. G. and Aldape K. D. (2005): Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res., 65, 1678-1686.
26. Omerovic J., Laude A. J. and Prior I. A. (2007): Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell. Mol. Life. Sci., 64, 2575-2589.
27. Rinker-Schaeffer C. W., O'Keefe J. P., Welch D. R. and Theodorescu D. (2006): Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin. Cancer Res., 12, 3882-3889.
28. Ruocco A., Santillo M., Cicale M., Serù R., Cuda G., Anrather J., Iadecola C., Postiglione A., Avvedimento E. V. and Paternò R. (2007): Farnesyl transferase inhibitors induce neuroprotection by inhibiting Ha-Ras signalling pathway. Eur. J. Neurosci., 26, 3261-3266.
29. Salazar M. D. (2004): Effects of monoterpene perillyl alcohol intranasal administration in peripheral lymphoid population and mucosal immune system of C57BL/6 mice. Laboratório de Patologia Celular, Instituto de Biologia, Universidade Federal Fluminense, Brazil.
30. Stayrook K. R., McKinzie J. H., Barbhaiya L. H. and Crowell P. L. (1998): Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res., 18, 823-828.
31. Teruszkin I., Alves S., Silva H. N., Curie C. M., Bozza M., Fonseca C. O. and Da Costa C. M. (2002). Effects of perillyl alcohol in glial cell line in vitro and anti-metastatic activity in chorioallantoic membrane model. Int. J. Mol. Med., 10, 785-788.